Compugen (CGEN) FCF Margin (2009 - 2010)
Compugen (CGEN) reported FCF Margin of 483.68% for Q4 2010, up 812032.0% on a YoY basis from N/an in Q4 2009, and up 94.38% sequentially from 8604.0% in Q4 2009.
Compugen (CGEN) FCF Margin (2009 - 2010) Analysis & Trends
Compugen (CGEN) has 2 years of FCF Margin data on file, last reported at 483.68% in Q4 2010.
- For the quarter ending Q4 2010, FCF Margin rose 812032.0% year-over-year to 483.68%; the trailing twelve-month figure through Dec 2010 stood at 113.95% (down 584173.0% YoY), and the FY2025 full-year result was 43.05%, down 13454.0% from the prior year.
- FCF Margin climbed to 483.68% in Q4 2010, from 8604.0% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 981.25% in Q3 2009 to a low of 8604.0% in Q4 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Compugen | 221.26 Mn | 129.51 Mn | 352,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | -483.68% |
| Dec 31, 2009 | -8,604.00% |
| Sep 30, 2009 | 981.25% |